Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41